Business Context and Reporting Period
Petco Health and Wellness Company, Inc. filed a Form 8-K under Item 5.02. The report identifies June 23, 2023 as the earliest event date and was signed on June 29, 2023. The filing concerns changes to the Company’s Board of Directors and committee assignments, not operating or financial results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Jennifer Pereira resigned from the Board effective June 23, 2023.
- Maximilian Biagosch notified the Board of his resignation effective June 29, 2023.
- The Company stated that neither resignation resulted from a disagreement with the Company or its operations, policies, or practices.
- Effective June 29, 2023, Iris Yen was appointed as an independent Class I director and to the Audit Committee, replacing Gary Briggs.
- Effective June 29, 2023, David Lubek was appointed as a Class II director and to the Nominating and Corporate Governance Committee, replacing Mary Sullivan.
- Mary Sullivan joined the Compensation Committee, succeeding Mr. Biagosch.
- Ms. Yen and Mr. Lubek were designated by the Company’s controlling stockholder, Scooby Aggregator, LP, under its director designation rights.
Compensation, Outlook, and Risks
- Ms. Yen will receive compensation under the Company’s independent director compensation program.
- The annual equity grant of restricted stock units for independent directors was increased from $150,000 to $165,000 effective July 6, 2023.
- Ms. Yen will also receive an initial restricted stock unit grant valued at approximately $120,000, vesting July 6, 2024, subject to continued Board service.
- The Company will enter into standard indemnification agreements with Ms. Yen and Mr. Lubek.
- The filing discloses no financial guidance, operational outlook, contingencies, or unusual financial items.
Important Facts to Verify
- Confirm the effective dates of the Board resignations and appointments, particularly the distinction between the June 23 report date and June 29 appointment and filing-signature date.
- Review subsequent filings for additional Board changes, committee composition, or changes to the controlling stockholder’s director designation rights.
- Verify the final terms, value, and vesting conditions of Ms. Yen’s annual and initial equity awards.
- Review the Company’s proxy statement and prior Form 10-K for the complete director compensation program and indemnification agreement.